Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

Changchun Deng, MD PhD, Mark Lipstein, Luigi Scotto, PhD, Xavier O Jirau Serrano, B.S., Michael Mangone, PhD, Shirong Li, PhD, Jeremie Vendome, PhD, Yun Hao, Xiaoming Xu, Xiaoping Liu, MD PhD, Ipsita Pal, PhD, Shi-Xian Deng, PhD, Nicholas P. Tatonetti, PhD, Suzanne Lentzsch, MD PhD, Barry Honig, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 291.

https://doi.org/10.1182/blood.V128.22.291.291

Published: 2016

Journal Articles

Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas

Changchun Deng, MD PhD, Mark Lipstein, Luigi Scotto, PhD, Yun Hao, Nicholas P. Tatonetti, PhD, Michael Mangone, PhD, Shirong Li, PhD, Suzanne Lentzsch, Ronald B. Realubit, PhD, Charles Karan, Jr., PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 593.

https://doi.org/10.1182/blood.V126.23.593.593

Published: 2015

Journal Articles

Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma

Changchun Deng, MD PhD, Mark Lipstein, B.S., Xavier Jirau Serrano, Michael Mangone, PhD, Luigi Scotto, PhD, Owen A O'Connor, MD, PhD, Peter Sportelli, Hari P. Miskin, MS, Srikant Viswanadha, PhD

Blood (2014) 124 (21): 1770.

https://doi.org/10.1182/blood.V124.21.1770.1770

Published: 2014

Journal Articles

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells

Changchun Deng, M.D, PH.D., Christine McIntosh, Richard Rodriguez, B.S., Peter Sportelli, Hari P. Miskin, MS, Swaroop Vakkalanka, PhD, Srikant Viswanadha, Ph.D., Mark Lipstein, B.S., Owen A. O'Connor, MD, PhD

Blood (2013) 122 (21): 4421.

https://doi.org/10.1182/blood.V122.21.4421.4421

Published: 2013

Journal Articles

Combination Of Selective HDAC Inhibitors That Target Specific HDAC Isoforms Synergistically Inhibits T Cell Lymphoma

Changchun Deng, MD, PhD, Richard Rodriguez, B.S., Christine McIntosh, Edward Holson, PH.D., Charles Karan, PH.D., Mark Lipstein, B.S., Owen A. O'Connor, MD, PhD

Blood (2013) 122 (21): 5142.

https://doi.org/10.1182/blood.V122.21.5142.5142

Published: 2013

NARROW

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas

Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells

Combination Of Selective HDAC Inhibitors That Target Specific HDAC Isoforms Synergistically Inhibits T Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas

Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells

Combination Of Selective HDAC Inhibitors That Target Specific HDAC Isoforms Synergistically Inhibits T Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only